Title |
-
en
High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients
|
Creator |
|
Accessrights |
open access |
Rights |
|
Subject |
-
Other
en
HNSCCs
-
Other
en
AMAP1
-
Other
en
EGFR
-
Other
en
Overall survival
-
Other
en
Disease free survival
-
NDC
490
|
Description |
-
Abstract
en
Background: Despite recent advances in cancer therapeutics in general, the survival of patients with head and neck squamous cell carcinomas (HNSCCs) has not improved substantially over the past few decades. HNSCC cells often exhibit invasive and metastatic phenotypes, and expression of epidermal growth factor receptor (EGFR) and cortactin has been highly implicated in the development of malignancy in HNSCCs. We have shown previously that an Arf6 pathway, in which Arf6 is activated by GEP100 and employs AMAP1 (also called DDEF1 or ASAP1) as its downstream effector, is pivotal for the invasion and metastasis of different breast cancer cells. This pathway is activated by receptor tyrosine kinases, including EGFR; and moreover, AMAP1 physically associates with cortactin, in which inhibition of this binding effectively blocks invasion and metastasis. We here investigated whether the expression of Arf6 pathway components correlates with the poor prognosis of HNSCC patients. We have shown previously that AMAP1 protein levels are not correlated with its mRNA levels, and hence we here employed immunohistochemical staining of HNSCC clinical specimens to investigate AMAP1 protein levels. Results: We found that high levels of AMAP1 protein expression on its own, as well as its co-overexpression with EGFR statistically correlates with poor disease-free survival and poor overall survival, while high levels of cortactin expression or its co-expression with EGFR did not. Conclusion: Our identification of predictive biomarkers, together with our previous findings on the coherent signaling pathway that these biomarkers ultimately generate should be powerful information for the further development of HNSCC therapeutics.
|
Publisher |
en
Biomed Central
|
Date |
|
Language |
|
Resource Type |
journal article |
Version Type |
VoR |
Identifier |
HDL
http://hdl.handle.net/2115/56334
|
Relation |
-
isIdenticalTo
DOI
https://doi.org/10.1186/1478-811X-12-17
-
PMID
24621372
|
Journal |
-
-
PISSN
1478-811X
-
NCID
AA12050544
-
en
Cell Communication and Signaling
-
Volume Number12
Page Start17
|
File |
|
Oaidate |
2023-07-26 |